Inter-species differences in sensitivity to the calcemic activity of the novel 1,25-dihydroxyvitamin D3 analog BXL746

Regulatory Toxicology and Pharmacology

Volumn 52, Issue 3, 2008, Pages 332-341

  Baroni, Enrico ^a   Camisa, Barbara ^a   D'Ambrosio, Daniele ^a  

^a BioXell SpA   (Italy)

Author keywords

Acute administration; Calcemia; Toxicity; Vitamin D3

Indexed keywords

1,25 DIHYDROXY 21 (3 HYDROXY 3 METHYLBUTYL)NORCHOLECALCIFEROL; BXL 746; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; MINERAL; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCEMIA; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CALCITRIOL; CALCIUM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERCALCEMIA; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OSSIFICATION, HETEROTOPIC; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC; TIME FACTORS; TOXICITY TESTS, CHRONIC;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 56049086828     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2008.09.002     Document Type: Article

References (37)

1. Adams J.S., Chen H., Chun R.F., Nguyen L., Wu S., Ren S.Y., Barsony J., and Gacad M.A. Novel regulators of vitamin D action and metabolism: Lessons learned at the Los Angeles zoo. J. Cell Biochem. 88 (2003) 308-314
2. Adams J.S., Chen H., Chun R., Gacad M.A., Encinas C., Ren S., Nguyen L., Wu S., Hewison M., and Barsony J. Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 461-465
3. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 233 (2005) 115-124
4. Agoston E.S., Hatcher M.A., Kensler T.W., and Posner G.H. Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med. Chem. 6 (2006) 53-71
5. Arbelle J.E., Chen H., Gaead M.A., Allegretto E.A., Pike J.W., and Adams J.S. Inhibition of vitamin D receptor-retinoid X receptor-vitamin D response element complex formation by nuclear extracts of vitamin D-resistant New World primate cells. Endocrinology 137 (1996) 786-789
6. Bailie G.R., and Johnson C.A. Comparative review of the pharmacokinetics of vitamin D analogues. Semin. Dial. 15 (2002) 352-357
7. Baroni E., Biffi M., Benigni F., Monno A., Carlucci D., Carmeliet G., Bouillon R., and D'Ambrosio D. VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3. J. Leukoc. Biol. 81 (2007) 250-262
8. Beer T.M., Munar M., and Henner W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91 (2001) 2431-2439
9. Beer T.M., Javle M., Lam G.N., Henner W.D., Wong A., and Trump D.L. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin. Cancer Res. 11 (2005) 7794-7799
10. Berezhkovskiy L.M. Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J. Pharmacokinet. Pharmacodyn. 33 (2006) 595-608
11. Bouillon R., Eelen G., Verlinden L., Mathieu C., Carmeliet G., and Verstuyf A. Vitamin D and cancer. J. Steroid Biochem. Mol. Biol. 102 (2006) 156-162
12. Brickman A.S., Reddy C.R., Coburn J.W., Passaro E.P., Jowsey J., and Norman A.W. Biologic action of 1, 25-dihydroxy-vitamin D3 in the rachitic dog. Endocrinology 92 (1973) 728-734
13. Chen H., Hu B., Allegretto E.A., and Adams J.S. The vitamin D response element-binding protein. A novel dominant-negative regulator of vitamin D-directed transactivation. J. Biol. Chem. 275 (2000) 35557-35564
14. Chen H., Hewison M., Hu B., and Adams J.S. Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc. Natl. Acad. Sci. USA 100 (2003) 6109-6114
15. Delmez J.A., Dougan C.S., Gearing B.K., Rothstein M., Windus D.W., Rapp N., and Slatopolsky E. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int. 31 (1987) 795-799
16. Dusso A.S., Brown A.J., and Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 289 (2005) F8-F28
17. Hamada C., Hayashi K., Shou I., Inaba M., Ro Y., Io H., Maeda K., Fukui M., and Tomino Y. Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit. Dial Int. 25 (2005) 570-575
18. Hilbe M., Sydler T., Fischer L., and Naegeli H. Metastatic calcification in a dog attributable to ingestion of a tacalcitol ointment. Vet. Pathol. 37 (2000) 490-492
19. How K.L., Hazewinkel H.A., and Mol J.A. Dietary vitamin D dependence of cat and dog due to inadequate cutaneous synthesis of vitamin D. Gen Comp Endocrinol. 96 (1994) 12-18
20. Hunt R.D., Garcia F.G., and Hegsted D.M. A comparison of vitamin D2 and D3 in New World primates I. Production and regression of osteodystrophia fibrosa. Lab. Anim. Care 17 (1967) 222-234
21. Ichikawa F., Katagiri K., Higuchi Y., Takeda S., and Saito K. 1Alpha-hydroxyvitamin D3 prevents the decrease of bone mineral density in lactating beagles. J. Vet. Med. Sci. 62 (2000) 75-79
22. Kubota M., Iwanaga Y., and Ishiguro N. The effect of intraperitoneal 22-oxacalcitriol on secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients (IPOX study). Adv. Perit. Dial. 19 (2003) 227-230
23. Malluche H.H., Matthews C., Faugere M.C., Fanti P., Endres D.B., and Friedler R.M. 1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology 119 (1986) 1298-1304
24. Marx S.J., Jones G., Weinstein R.S., Chrousos G.P., and Renquist D.M. Differences in mineral metabolism among nonhuman primates receiving diets with only vitamin D3 or only vitamin D2. J. Clin. Endocrinol. Metab. 69 (1989) 1282-1290
25. Masuda S., and Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther. 5 (2006) 797-808
26. Mathieu C., and Adorini L. The coming of age of 1, 25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 8 (2002) 174-179
27. MHRA, 2007. Curatoderm 4 micrograms/g lotion. United Kingdom Public Assessment Report. PL00327/0149.
28. Monier-Faugere M.C., Geng Z., Friedler R.M., Qi Q., Kubodera N., Slatopolsky E., and Malluche H.H. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int. 55 (1999) 821-832
29. Murakami K., Miyachi H., Watanabe A., Kawamura N., Fujii M., Koide S., Murase M., Kushimoto H., Hasegawa M., Tomita M., Hiki Y., and Sugiyama S. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol. Clin. Exp. Nephrol. 8 (2004) 134-138
30. Penna G., and Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164 (2000) 2405-2411
31. Puschett J.B., Moranz J., and Kurnick W.S. Evidence for a direct action of cholecalciferol and 25-hydroxycholecalciferol on the renal transport of phosphate, sodium, and calcium. J. Clin. Invest. 51 (1972) 373-385
32. Salusky I.B., Kuizon B.D., Belin T.R., Ramirez J.A., Gales B., Segre G.V., and Goodman W.G. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 54 (1998) 907-914
33. Salusky I.B., Goodman W.G., Horst R., Segre G.V., Kim L., Norris K.C., Adams J.S., Holloway M., Fine R.N., and Coburn J.W. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am. J. Kidney Dis. 16 (1990) 126-132
34. Shinki T., Shiina Y., Takahashi N., Tanioka Y., Koizumi H., and Suda T. Extremely high circulating levels of 1 alpha, 25-dihydroxyvitamin D3 in the marmoset, a new world monkey. Biochem. Biophys. Res. Commun. 114 (1983) 452-457
35. Spina C.S., Tangpricha V., Uskokovic M., Adorinic L., Maehr H., and Holick M.F. Vitamin D and cancer. Anticancer Res. 26 (2006) 2515-2524
36. Takahashi F., Furuichi T., Yorozu K., Kawata S., Kitamura H., Kubodera N., and Slatopolsky E. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure. Nephrol. Dial. Transplant. 17 Suppl. 10 (2002) 46-52
37. Vieth R. Vitamin D toxicity, policy, and science. J. Bone Miner. Res. 22 Suppl. 2 (2007) V64-V68